Scinopharm Taiwan, Ltd. · TWSE:1789
Scinopharm Taiwan — H1 2018 Earnings Presentation
23 slides from Scinopharm Taiwan's earnings presentation, Aug 2, 2018
Slide 1: ScinoPharm Taiwan, Ltd. H1 2018 On-Line Investor Meeting
1789 TT ScinoPharm Taiwan, Ltd. H1 2018 On-Line Investor Meeting August 2, 2018
Slide 2: Disclaimer
Disclaimer This material has been prepared by ScinoPharm Taiwan, Ltd. (“ScinoPharm”). Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. ScinoPharm is under no obligation to update or keep current the information contained herein.
Slide 3: Table of Content
Table of Content Overall Updates of ScinoPharm Business Updates Financial & Operating Results in H1, 2018 3
Slide 4: Overall Updates of ScinoPharm
Overall Updates of ScinoPharm 4
Slide 5: ScinoPharm at a Glance
ScinoPharm at a Glance ScinoPharm specializes in high potency (steroid/cytotoxic) APIs and injectable provider, serving customers worldwide Facility & offices established in Taiwan and expanding in China with a new GMP plant in Changshu & marketing base in Shanghai 71 generic APIs in current portfol
Slide 6: Driving Long Term Growth by Dual Profits
Driving Long Term Growth by Dual Profits Self-Developed Contract Products Services Target difficult-to-make (peptide)API in our Provide CRO/CMO for APIs portfolio Offer integrated service Tap into drug product from API to formulation related to our API core for niche injectables competencies Provide
Slide 7: Strong API Portfolio for Generic Product
Strong API Portfolio for Generic Product 40 35 unlaunched 35 launched 30 25 22 20 13 15 10 7 7 6 13 2 2 2 3 3 5 6 6 4 1 3 2 1 1 2 1 0 Note: Others (Women's Health, Respiratory and Immunology ) 7
Slide 8: Recap of Performances and Major Events
Recap of Performances and Major Events Reported the consolidated revenues for H1 2018 were NT$1.847 billion, net profits after-tax were NT$ 267 million, gross margin was 41%, EPS was NT$0.34 Financial performances were mainly benefited from the favorable sales volumes for colorectal cancer product o
Slide 9: Business Updates
Business Updates 9
Slide 10: Strategic Alliance Highlights
Strategic Alliance Highlights * launched Partner Product Indications Region Launch Year(E) Remarks Genovate Entecavir Hepatitis B Virus Taiwan 2013* 1st co-developed formulation product launch Oncology 1st US ANDA filing, triggering US FDA inspection Myeloid Sagent US 2018* in Changshu, China site.
Slide 11: CRO Phase III Products Portfolio
CRO Phase III Products Portfolio NDA Filing Indication Region Remarks Year (E) Type I Intermediate project made both in Changshu & 2018 Diabetes Taiwan. Type I anticipated launch in 2019.Type II US/ EU Type II expected submission in 2019. Expected revenue 2019 of several million USD per year after a
Slide 12: 2018 CPhI China Observations
2018 CPhI China Observations Fewer Western exhibitors in CPhI Trade Show this year New drug flourishing as new guidelines make China a more drug-friendly market As government is cracking down on noncompliance with environmental rules, API producers were buffeted by raw material and intermediate fact
Slide 13: H1 2018 TOP 5 Products
H1 2018 TOP 5 Products Ranking API Product Indication Breast, Ovarian 1 Paclitaxel and Lung Cancer 2 Irinotecan HCI Colorectal Cancer 3 Intermediates for CRAM project Diabetes Pancreatic, Non-Small-Cell 4 Gemcitabine Hydrochloride Lung Cancer Breast, Non-Small-Cell 5 Docetaxel Anhydrous Lung Cancer
Slide 14: 2018 Product Launch Plan
2018 Product Launch Plan Brand Regional Type Product Region Indication WW Sales Marketer Sales Tamsulosin Benign Prostatic Boehringer Generic API CN US$97MM US$1,731m HCl Hyperplasia (BPH) Ingelheim Reversal of Conscious Generic API Flumazenil JP Sedation and General Roche US$13.5MM US$78.4m Anesthe
Slide 15: Financial & Operating Results H1, 2018
Financial & Operating Results H1, 2018 15
Slide 16: Quarterly P&L - Consolidated
Quarterly P&L - Consolidated In NT$ million, except for EPS Q2 2018 Q1 2018 Q2 2017 (Reviewed) (Reviewed) QoQ (Reviewed) YoY Revenue 986 100% 861 100% 14% 853 100% 16% Cost of Goods Sold (565) -57% (527) -61% -7% (527) -62% -7% Gross Profit 421 43% 335 39% 26% 326 38% 29% Operating Expense (261) -26
Slide 17: Profit & Loss - Consolidated
Profit & Loss - Consolidated In NT$ million, except for EPS H1 2018 H1 2017 (Reviewed) (Reviewed) YoY Revenue 1,847 100% 1,773 100% 4% (note) Cost of Goods Sold (1,092) -59% (977) -55% -12% Gross Profit 755 41% 796 45% -5% Operating Expense (474) -26% (488) -28% 3% Operating Income 281 15% 308 17% -
Slide 18: Sales by Business
Sales by Business 2018 H1 BD& 2017 H1 CMO Other 15% 1% BD& CRO Other 5% CMO 8% 8% Generics CRO 79% 8% Generics 76% 18
Slide 19: Sales by Indications
Sales by Indications 2018 H1 Others Infectious CNS 17% 3% 2017 H1 10% Others 20% CNS Oncology 12% 70% Oncology 68% 19
Slide 20: Sales by Region
Sales by Region 2018 H1 ROW 2017 H1 JP CN 6% 8% 1% India ROW JP CN 10% US+CAN 11% 7% 2% 36% India EU 6% 39% US+CAN 39% EU 35% 20
Slide 21: Balance Sheet- Consolidated
Balance Sheet- Consolidated (In NT$ million) 2018/06/30 2017/06/30 (Reviewed) (Reviewed) Cash and Cash Equivalents 4,017 30% 3,721 29% Financial asset measured at amortised cost 275 2% - 0% Accounts Receivable 709 5% 726 6% Inventories 1,517 11% 1,802 14% Financial asset measured at fair value throu
Slide 22: Cash Flows- Consolidated
Cash Flows- Consolidated (In NT$ million) H1 2018 H1 2017 (Reviewed) (Reviewed) From Operating Actavities 370 353 Profit before tax 248 272 Depreciation & Amortisation 208 221 Net change in working capital (86) (140) From Investing Actavities (350) (351) Financial asset measured at amortised cost (2
Slide 23: Brand Quality with Asian Advantages
Brand Quality with Asian Advantages www.scinopharm.com 1789 TT 23